Results of stem cell transplants in children with blood diseases and cancers
Follows outcomes and complications of stem cell transplants in children with blood diseases and cancers.
Plain-language title generated from the registry record
Registry title: Outcome of HSCT in Children at Ramathibodi Hospital
Key facts
- Where
- Ratchathewi, ThailandSee the site
Where in Thailand
- Ramathibodi HospitalRatchathewi, ThailandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mahidol University
- Trial code
- NCT07857746
- Record updated
- 5 October 2026
- Original description
Firstly, to study the treatment outcomes of hematopoietic stem cell transplantation (HSCT) in patients with hematologic diseases, cancers, and other conditions treated at the Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital. Secondly, to evaluate factors that may influence treatment outcomes in patients with hematologic diseases, cancers, and other conditions undergoing hematopoietic stem cell transplantation. Lastly, to study complications occurring after hematopoietic stem cell transplantation in patients with hematologic diseases, cancers, and other conditions, in order to identify opportunities to further improve treatment outcomes.Read full original descriptionShow less
Outcome of Hematopoietic Stem Cell Transplantation in Children With Hematologic, Malignant and Other Diseases at Ramathibodi Hospital
Firstly, to study the treatment outcomes of hematopoietic stem cell transplantation (HSCT) in patients with hematologic diseases, cancers, and other conditions treated at the Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital. Secondly, to evaluate factors that may influence treatment outcomes in patients with hematologic diseases, cancers, and other conditions undergoing hematopoietic stem cell transplantation. Lastly, to study complications occurring after hematopoietic stem cell transplantation in patients with hematologic diseases, cancers, and other conditions, in order to identify opportunities to further improve treatment outcomes.
Inclusion: Patients with hematologic, malignant, or other diseases who underwent HSCT.
Exclusion: Incomplete or loss of medical records.